Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

7.430 -0.240 (-3.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,892,732
Open 7.270
Bid (Size) 7.050 (2)
Ask (Size) 7.650 (1)
Prev. Close 7.670
Today's Range 7.113 - 7.680
52wk Range 2.280 - 9.010
Shares Outstanding 144,311,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations For Adaptive Biotechnologies's Future
Via Benzinga
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday
Via Benzinga

Performance

YTD
+20.0%
+20.0%
1 Month
-8.3%
-8.3%
3 Month
+21.6%
+21.6%
6 Month
+45.1%
+45.1%
1 Year
+138.9%
+138.9%

More News

Read More
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled
Via Talk Markets
Topics ETFs Stocks / Equities
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
Via Benzinga
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
Earnings Scheduled For February 11, 2025
Via Benzinga
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
Via Investor's Business Daily
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Via Benzinga
Topics Workforce
Exposures Layoff
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks
Via Talk Markets
Topics ETFs Stocks / Equities
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Top 3 Health Care Stocks That May Collapse This Quarter
Via Benzinga
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire

Frequently Asked Questions

Is Adaptive Biotechnologies Corporation - Common Stock publicly traded?
Yes, Adaptive Biotechnologies Corporation - Common Stock is publicly traded.
What exchange does Adaptive Biotechnologies Corporation - Common Stock trade on?
Adaptive Biotechnologies Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Adaptive Biotechnologies Corporation - Common Stock?
The ticker symbol for Adaptive Biotechnologies Corporation - Common Stock is ADPT on the Nasdaq Stock Market
What is the current price of Adaptive Biotechnologies Corporation - Common Stock?
The current price of Adaptive Biotechnologies Corporation - Common Stock is 7.430
When was Adaptive Biotechnologies Corporation - Common Stock last traded?
The last trade of Adaptive Biotechnologies Corporation - Common Stock was at 03/31/25 04:00 PM ET
What is the market capitalization of Adaptive Biotechnologies Corporation - Common Stock?
The market capitalization of Adaptive Biotechnologies Corporation - Common Stock is 1.07B
How many shares of Adaptive Biotechnologies Corporation - Common Stock are outstanding?
Adaptive Biotechnologies Corporation - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.